Ionis Pharmaceuticals (IONS) Reports Q4 Earnings: What Key Metrics Have to Say

For the quarter ended December 2024, Ionis Pharmaceuticals (IONS) reported revenue of $227 million, down 30.2% over the same period last year. EPS came in at -$0.66, compared to -$0.06 in the year-ago quarter.The reported revenue represents a surprise of +65.19% over the Zacks Consensus Estimate of $137.42 million. With the consensus EPS estimate being -$1.12, the EPS surprise was +41.07%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Ionis Pharmaceuticals performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenue- Total commercial revenue: $86 million compared to the $80.55 million average estimate based on eight analysts. The reported number represents a change of +8.9% year over year. Revenue- Commercial revenue- SPINRAZA royalties: $64 million versus the eight-analyst average estimate of $60.73 million. The reported number represents a year-over-year change of +3.2%. Revenue- Commercial revenue- Other commercial revenue- Licensing and other royalty revenue: $4 million compared to the $5.23 million average estimate based on eight analysts. The reported number represents a change of -50% year over year. Revenue- Commercial revenue- Other commercial revenue- TEGSEDI and WAYLIVRA revenue, net: $8 million versus $7.06 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a -11.1% change. Revenue- Total research and development revenue: $141 million compared to the $56.86 million average estimate based on seven analysts. Revenue- Commercial revenue- Other commercial revenue: $12 million versus $13.30 million estimated by six analysts on average. Revenue- Commercial revenue- WAINUA royalties: $10 million compared to the $7.94 million average estimate based on six analysts. Revenue- Research and development revenue- Collaborative agreement revenue: $97 million versus the five-analyst average estimate of $43.79 million. The reported number represents a year-over-year change of -45.8%. Revenue- Research and development revenue- WAINUA joint development revenue: $44 million versus $14.30 million estimated by four analysts on average. View all Key Company Metrics for Ionis Pharmaceuticals here>>>Shares of Ionis Pharmaceuticals have returned -2.2% over the past month versus the Zacks S&P 500 composite's +4.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Ionis Pharmaceuticals, Inc. (IONS): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks